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Abstract
AIM: To investigate the angiogenesis-related protein 
expression profile characterizing metastatic colorectal 
cancer (mCRC) with the aim of identifying prognostic 
markers. 
METHODS: The expression of 44 angiogenesis-
secreted factors was measured by a novel cytokine 
antibody array methodology. The study evaluated vas-
cular endothelial growth factor (VEGF) and its soluble 
vascular endothelial growth factor receptor (sVEGFR)-1 
protein levels by enzyme immunoassay (EIA) in a panel 
of 16 CRC cell lines. mRNA VEGF and VEGF-A isoforms 
were quantified by quantitative reverse-transcription 
polymerase chain reaction (Q-RT-PCR) and vascular en-
dothelial growth factor receptor (VEGFR)-2 expression 
was analyzed by flow cytometry. 
RESULTS: Metastasis-derived CRC cell lines expressed 
a distinctive molecular profile as compared with those 
isolated from a primary tumor site. Metastatic CRC 
cell lines were characterized by higher expression of 
angiopoietin-2 (Ang-2), macrophage chemoattractant 
proteins-3/4 (MCP-3/4), matrix metalloproteinase-1 
(MMP-1), and the chemokines interferon γ inducible 
T cell α chemoattractant protein (I-TAC), monocyte 
chemoattractant protein I-309, and interleukins inter-
leukin (IL)-2 and IL-1α, as compared to primary tumor 
cell lines. In contrast, primary CRC cell lines expressed 
higher levels of interferon γ (IFN-γ), insulin-like growth 
factor-1 (IGF-1), IL-6, leptin, epidermal growth factor 
(EGF), placental growth factor (PlGF), thrombopoietin, 
transforming growth factor β1 (TGF-β1) and VEGF-D, 
as compared with the metastatic cell lines. VEGF ex-
pression does not significantly differ according to the 
CRC cellular origin in normoxia. Severe hypoxia in-
duced VEGF expression up-regulation but contrary to 
expectations, metastatic CRC cell lines did not respond 
as much as primary cell lines to the hypoxic stimulus. 
In CRC primary-derived cell lines, we observed a two-
fold increase in VEGF expression between normoxia 
and hypoxia as compared to metastatic cell lines. CRC 
cell lines express a similar pattern of VEGF isoforms 
(VEGF121, VEGF165 and VEGF189) despite variability in 
VEGF expression, where the major transcript was 
VEGF121. No relevant expression of VEGFR-2 was found 
in CRC cell lines, as compared to that of human umbili-
cal vein endothelial cells and sVEGFR-1 expression did 
not depend on the CRC cellular origin. 
CONCLUSION: A distinct angiogenesis-related expres-
sion pattern characterizes metastatic CRC cell lines. 
Factors other than VEGF appear as prognostic markers 
and intervention targets in the metastatic CRC setting. 
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Colorectal cancer (CRC) is one of  the leading causes of  
cancer-related deaths. The prognosis of  CRC is depen-
dent upon the extent of  disease and approximately 60% 
of  patients develop metastases after surgical resection. 
With a 5-year survival rate of  less than 10% in patients 
with distant metastatic disease, targeting the metastatic 
process and sites should provide an effective treatment[1]. 
The progressive growth of  colon cancer and subsequent 
metastatic process is dependent on an angiogenic net-
work[2,3]. Thus, anti-angiogenic strategies have emerged 
as effective therapies in patients with colon cancer, es-
pecially in the metastatic setting of  the disease[4-6]. Yet, 
differences in the magnitude of  survival benefit point to 
alternative pathways in the tumor microenvironment as 
responsible for inconsistent outcomes[7].
Angiogenesis is a complex process dependent on the 
angiogenic factors secreted by the tumor and stroma cells[8]. 
Vascular endothelial growth factor is considered the major 
pro-angiogenic factor[9]. The vascular endothelial growth 
factor (VEGF) gene encodes for six alternatively spliced 
isoforms[10] with differential diffusion potential and bind-
ing to receptors[11]. The question currently consists of  
understanding the significance of  VEGF/vascular endo-
thelial growth factor receptor (VEGFR) signaling in can-
cer cells[12,13]. The VEGF isoforms and VEGF receptor 
expression pattern would drive the activity and functional-
ity of  the VEGF/VEGFR pathway in both tumor and 
endothelial cells. The multistep process of  angiogenesis 
accompanies the multistage development of  a tumor[14]. 
The switch into the metastatic phenotype brings a number 
of  changes within the tumor microenvironment, includ-
ing acquisition of  hypoxia-tolerance mechanisms[15]. While 
up-regulation of  VEGF expression is activated mainly 
under hypoxia[9], recent reports reflect on the question of  
whether metastatic tumors rely as much on angiogenesis 
and VEGF as primary tumors[15].
Other studies report that tumors in more advanced 
stages do not rely on a unique angiogenesis driver[2]. A 
network of  multiple cytokines and growth factors create 
a crosstalk within the tumor microenvironment which 
ultimately drives tumor angiogenesis[2,16]. The mediators 
of  vessel wall remodeling matrix metalloproteinases, 
macrophage chemoattractant proteins and angiopoietin, 
involved in invasion and metastasis processes, exert pro-
angiogenic signals[8,17]. Chemokines such as interleukin 
(IL)-1α and IL-8 play an important role in colon cancer 
progression and angiogenesis[18], and IL-8 up-regulates 
MMPs[19]. VEGF expression actually determines the ac-
tivity of  Ang-1/Ang-2 and the expression of  MCPs[20,21].
Great efforts have been made to characterize biomark-
ers in CRC[22]. However, the question of  biomarkers of  
CRC metastasis remains currently unresolved. On this 
basis, the aim of  this study was to characterize the protein 
factors behind the angiogenic potential of  CRC cell lines 
of  metastatic origin.
MATERIALS AND METHODS
Cell cultures and conditioned media
We used 16 CRC cell lines: HT29, WiDr, HCT116, RKO, 
SW480, Colo320, Caco2, SW1116, LS174T, SW1417, DLD-1, 
LS513, HCT15, SW620, LoVo and T84 (all from American 
Type Culture Collection, Manassas, VA) (Table 1). The cell 
lines were maintained in the recommended growth media 
supplemented with 10% fetal bovine serum (GIBCO) 
and 1% penicillin/streptomycin (GIBCO). For harvesting 
conditioned media, CRC lines cells were grown approxi-
mately to 70% confluence in serum free media. The con-
ditioned media were collected after 24 h of  incubation, 
centrifuged and kept frozen.
VEGF and sVEGFR1 protein detection by quantitative 
immunoassay
VEGF-A in supernatant was determined using the Hu-
man VEGF Quantikine® EIA kit (R and D Systems) 
and soluble vascular endothelial growth factor receptor 
(sVEGFR)-1 was quantified by EIA (Human sVEGF 
638 February 21, 2012|Volume 18|Issue 7|WJG|www.wjgnet.com
Abajo A et al . Angiogenic profile of colorectal cancer metastasis
Table 1  Colorectal cancer cell lines origin
Cell line Type/origin
SW620 Colon adenocarcinoma. Derived from: metastasis to 
lymph node
T84 Colon carcinoma. Derived from metastasis to lung
LoVo Derived from metastatic site: left supraclavicular region
SW480 Colon adenocarcinoma
WiDr Colon adenocarcinoma
RKO Colon carcinoma
HT29 Colon adenocarcinoma
HCT15 Colon adenocarcinoma
HCT116 Colon carcinoma
SW1116 Colon adenocarcinoma
SW1417 Colon adenocarcinoma
LS174T Colon adenocarcinoma
LS513 Colon carcinoma
Caco2 Colon adenocarcinoma
DLD-1 Colon adenocarcinoma
LS411N Colon adenocarcinoma
Colo320 Colon adenocarcinoma
R1/Flt-1 Quantikine®, R and D Systems), according to 
the manufacturer’s instructions. We normalized VEGF 
and sVEGFR-1 protein levels per number of  cells. Re-
sults are the average of  replicates.
Total VEGF and isoforms mRNA determination by 
quantitative reverse-transcription polymerase chain 
reaction
Total RNA was isolated using the RNeasy kit (Qiagen, 
Valencia, CA). Single strand DNA was synthesized from 
1 μg total RNA using the cDNA Archive kit (Applied 
Biosystems). Quantitative reverse-transcription polymerase 
chain reaction (Q-RT-PCR) for total VEGF was per-
formed using primers and probes purchased from Applied 
Biosystems (Hs00900054_m1). RNA18s (Hs99999901_s1) 
was used as an endogenous control and data obtained was 
represented as 2-∆Ct.
VEGF isoforms were determined by Q-RT-PCR us-
ing primers designed specifically for VEGF121, VEGF165, 
and VEGF189, and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an endogenous control 
(Table 2). The relative quantification of  samples was per-
formed using a standard curve by dilution of  a specific 
plasmid for each isoform (ranging from 10 pg to 1 fg). 
Human VEGF cDNA for each isoform and GAPDH 
were cloned from total RNA isolated from lung cancer 
resection as follows. PCR products were run through a 
1% agar gel and bands of  the size expected for VEGF121, 
VEGF165 and VEGF189 were isolated and purified. Each 
VEGF isoform was cloned into the pCRII vector (Invit-
rogen) and sequenced (ABI PRISM Big Dye Terminator 
Cycle Sequencing reaction kit; ABI Protocol, Gene Amp 
9600, Applied Biosystems) to verify its identity. 
Time course hypoxia-normoxia
The cell lines were maintained in the recommended 
growth media supplemented with 10% fetal bovine se-
rum (GIBCO) and 1% penicillin/streptomycin (GIBCO). 
After washing with phosphate buffered saline (PBS), 
serum-free medium was added and the cells exposed to 
normoxic or hypoxic conditions for 6 h, 12 h, 24 h, 36 
h, 48 h and 72 h. Hypoxic conditions were achieved by 
culturing cells in a modulator incubation chamber (Sanyo 
MCO-18 M) gassed with 1% O2, 50 mL/L CO2, and 
94% N2. VEGF protein secretion was measured in the 
supernatant by enzyme immune-assay (EIA) and VEGF 
mRNA levels by Q-RT-PCR. Cell proliferation was evalu-
ated by the Trypan Blue exclusion method.
VEGFR-2 expression in colorectal cancer cell lines by 
flow cytometry
The expression of  VEGFR-2 (KDR) in CRC cell lines 
was determined by flow cytometry (FacScan, Becton-
Dickinson). After trypsinization, cells were incubated 
in medium for 12 h on a rocker platform to enable re-
generation of  the receptors. Cells were Fc-blocked by 
treatment with 100 μL of  AB human serum for 15 min 
at room temperature prior to staining with 10 μL of  PE-
conjugated anti-VEGFR-2 antibody (Becton Dickinson 
Biosystems) for 30 min at 4  ℃. Following the incubation, 
unbounded anti-VEGFR-2 antibody was removed by 
washing the cells twice in 4 mL PBS buffer. The human 
umbilical vein endothelial cells (HUVEC) cell line was 
used as a positive control. 
Secreted angiogenic profile by cytokine antibody-array 
The secretion of  angiogenic factors by CRC cell lines 
was evaluated in duplicate using a protein array method 
(RayBio® Human Angiogenesis Antibody Array, RayBio-
tech C Series 1000, RayBiotech, Inc Norgross, GA). This 
assay is capable of  simultaneously detecting 44 different 
angiogenic factors (spotted in sub-arrays Ⅰ and Ⅱ) with 
high specificity. The sensitivity of  the antibodies present 
in the arrays ranged from 1-2000 pg/mL. Conditioned 
media was obtained after the incubation of  2 × 105 cells 
in serum-free medium for 20 h at 37  ℃ and 5% CO2. 
Each array was incubated with 1.2 mL of  medium at 4  ℃ 
overnight, and bound antigens were detected according 
to the manufacturer’s instructions. To determine the rela-
tive concentrations of  angiogenic factors in the media, 
the densities of  individual spots were measured using 
Imagene 4.1 software (Biodiscovery Inc., Marina Del Rey, 
United States) for image capture and analysis.
Statistical analysis
Statistical analysis was carried out with SPSS 13.0 soft-
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Table 2  Primer and probe sequences for vascular endothelial growth factor isoforms quantitative reverse-transcription polymerase 
chain reaction
Sense primer Antisense primer Taqman probe Amplicon 
size (bp)
VEGF end-point 
and cloning
ACTGCCATCCAATCGAGACC GATGGCTTGAAGATGTACTCGATCT
GAPDH end-
point and cloning
TGGTATCGTGGAAGGACTCATGAC ATGCCAGTGAGCTTCCCGTTCAGC 189
VEGF121 mRNA CAAGGCCAGCACATAGGAGA CTCGGCTTGTCACATTTTTC CTTCCTACAGCACAACAAATGT-
GAATGCAGA
101
VEGF165 mRNA TGTGAATGCAGACCAAAGAAAGA TGCTTTCTCCGCTCTGAGC AGAGCAAGACAAGAAAATCCCT-
GTGGGC
  74
VEGF189 mRNA CGCAAGAAATCCCGGTATAAGT TGCTTTCTCCGCTCTGAGC AGGCCCACAGGGAACGCTCCAG   65
GAPDH TGGTATCGTGGAAGGACTCATGAC ATGCCAGTGAGCTTCCCGTTCAGC CCCAGAGACTGTGGATGGCCCC 189
VEGF: Vascular endothelial growth factor; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
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RESULTS
Distinct angiogenesis-related expression pattern in 
primary and metastatic colorectal cancer cell lines
To identify the angiogenesis-related “secretome” of  CRC 
cell lines in normoxia, we analyzed 44 angiogenesis-
related cytokines and growth factors by an antibody-array 
in primary (Caco2, SW1417, DLD1, HT29 and SW480) 
and metastatic (SW620 and T84) CRC cell lines. K-means 
analysis classified CRC cell line angiogenesis-related se-
creted factors according to their level of  secretion (Figure 
1A). Cluster Ⅰ showed a homogeneous high expression 
of  the pro-angiogenic IL-8, MMP-1, MCP-1, growth 
related oncogene (GRO)-α, regulated upon activation, 
ware (SPSS Inc.). Associations between VEGF expres-
sion and VEGF isoforms pattern were determined with 
the Spearman correlation. Differences between groups 
were determined by the Mann-Whitney U test. The level 
of  two-tailed statistical significance was 0.05. 
CRC cell line angiogenesis cytokine antibody-arrays 
raw data were normalized to the global median [BRB Ar-
ray Tools 3.6.0 (NCI)] of  signals detected as per manu-
facturer’s instructions. GENESIS software (Institute for 
biomedical engineering, Graz University of  Technology, 
Graz, Austria) was used for the analyses of  clustering of  
samples and genes and K-means and hierarchical unsu-
pervised clustering analyses were performed to determine 
cytokine profiles. 
Cluster 1-9 genes Cluster 3-11 genes Cluster 2-9 genes Cluster 4-10 genes
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Figure 1  Angiogenesis-related factors expression profile in colorectal cancer cell lines as determined by cytokine antibody-array. A: K-means (n = 4) clus-
tering grouped the angiogenesis-related proteins according to level of expression; B: Unsupervised-hierarchical clustering of the factors with a significantly different 
expression in primary and metastatic colorectal cancer (CRC) cell lines; C: Images of subarrays Ⅰ and Ⅱ of the primary Caco2 and the metastatic T84 CRC cell 
lines after detection and processing. IL: Interleukin; MMP: Matrix metalloproteinase; TIMP: Tissue inhibitor of metalloproteinases; GRO: Growth related oncogene; 
MCP: Macrophage chemoattractant proteins; RANTES: Regulated upon activation normally T-expressed and secreted; uPAR: Urokinase-type plasminogen activator-
receptor; G-CSF: Granulocyte colony-stimulating factor; PIGF: Phosphatidylinositol glycan, class F; TNF-α: Tumor necrosis factor-α; GM-CSF: Granulocyte mac-
rophage colony-stimulating factor; IFN-γ: Interferon γ; IGF: Insulin-like growth factor; PECAM: Platelet-endothelial cell adhesion molecule; I-TAC: Inducible T cell α 
chemoattractant protein; ENA: Epithelial neutrophil activating protein; EGF: Epidermal growth factor; PDGF-BB: Platelet-derived growth factor, β polypeptide; TGF-β1: 
Transforming growth factor β1; Neg: Negative control; Pos: Positive control.
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normal T-cell expressed, and secreted protein (RANTES), 
urokinase-type plasminogen activator-receptor (uPAR) 
and VEGF; and the anti-angiogenic tissue inhibitor of  
metalloproteinases tissue inhibitor of  metalloproteinases 
(TIMP)-1 and TIMP-2 (Figure 1A, cluster Ⅰ). Cluster Ⅱ 
integrated angiogenic factors not secreted by CRC cell 
lines in normoxia, including VEGF family proteins pla-
cental growth factor (PlGF) and sVEGFR-2 and inflam-
matory cytokines with pro-angiogenic properties granu-
locyte colony-stimulating factor (G-CSF), granulocyte 
macrophage colony-stimulating factor (GM-CSF), IFN-γ, 
tumor necrosis factor-α (TNF-α) (Figure 1A, cluster Ⅱ). 
Primary tumor- and metastasis-derived CRC cell lines 
were characterized by a distinct angiogenesis-related mo-
lecular pattern in normoxia (Figure 1A, cluster Ⅲ and Ⅳ). 
Figure 1B shows the unsupervised hierarchical clustering 
of  the antibody-array proteins significantly differing in 
expression according to their cellular origin. One-way 
ANOVA (P < 0.05) grouped primary and metastatic cell 
lines according to their differential molecular expression 
pattern. Metastasis-derived cell lines were characterized 
by higher expression of  Ang-2, MCP-3, MCP-4, MMP-1 
and the chemokines I-TAC, I-309, IL-2 and IL-1α (P < 
0.05), and a trend was found for MMP-9, as compared to 
primary tumor cell lines (Figure 1B). On the other hand, 
CRC cell lines isolated from a primary tumor site were 
clustered together according to the higher expression of  
IFN-γ, IGF-1, IL-6, leptin, EGF, PlGF, thrombopoietin, 
TGF-β1 and VEGF-D (P < 0.05), as compared with 
the metastatic ones (Figure 1B). Interestingly, VEGF-A 
(VEGF) was not found among the proteins differentially 
expressed according to the cellular source of  isolation. 
Figure 1C illustrates processed antibody-arrays and the 
images captured of  Caco2 (primary CRC cell line) and 
T84 (metastatic CRC cell line).
VEGF expression in primary and metastatic colorectal 
cancer cell lines
The antibody array data showed no significant changes 
in VEGF secretion between primary and metastasis-de-
rived CRC cell lines (Figure 1B). To validate the antibody 
array results, we analyzed VEGF levels by EIA. The re-
sults were confirmed by a statistically significant positive 
correlation between VEGF protein as determined by 
the antibody-array and by EIA (r Spearman = 0.7, P < 0.05) 
(Figure 2A). 
In a second step, VEGF secretion by EIA and VEGF 
mRNA expression was analyzed in a larger panel of  16 
CRC cell lines. As shown in Figure 2B and C, we did not 
detect any significant difference in VEGF expression 
according to the primary or metastatic CRC cell lines 
(mean of  28.9 pg/mL and 22.7 pg/mL VEGF protein; 
0.011 and 0.009 (relative quantification) VEGF mRNA, 
respectively). Further, a strong correlation (r = 0.65, P < 
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0.01) was detected between VEGF protein (by EIA) and 
VEGF mRNA expression (Figure 2D) in CRC cell lines, 
indicative of  the major role of  transcriptional mecha-
nisms in the regulation of  VEGF expression[23]. A similar 
correlation was observed in hypoxia between VEGF pro-
tein (by EIA) and VEGF mRNA expression (Figure 3A). 
Severe hypoxia induced different levels of  VEGF expres-
sion up-regulation depending on the CRC cellular origin. 
Surprisingly, the fold change normoxia-hypoxia in VEGF 
expression of  metastatic CRC cell lines was ≤ 1.5 in the 
majority of  time points tested, as compared with the > 
1.5-4.0 fold change in primary cell lines for both protein 
and mRNA VEGF (Figure 3A).
VEGF isoforms have differential angiogenic and 
tumorigenic activities and their expression pattern may 
also define the CRC cell angiogenic capacity[24]. Primary 
and metastatic CRC cell lines had a similar expression 
pattern of  the three major isoforms VEGF121, VEGF169 
and VEGF185, despite variability in VEGF expression 
(Figure 3B), implying a similar mechanism of  regulation. 
VEGF121 was the predominant isoform expressed by 
CRC cell lines (58.23% ± 5.05% of  total VEGF mRNA), 
as compared toVEGF165 and VEGF189 (15.13% ± 2.71% 
and 26.6% ± 6.5% of  VEGF transcripts, respectively). In 
line with a previous study on tumor tissue[25], the expres-
sion of  the three isoforms was significantly associated 
with total VEGF protein; r = 0.55, P < 0.05 for VEGF121 
and furthermore, VEGF165 and VEGF189 showed higher 
correlation (r = 0.67 and r = 0.69, P < 0.01, respectively) 
(Table 3).
VEGFR expression in colorectal cancer cell lines
While the role of  the VEGF/VEGFR pathway in en-
dothelial cells is well characterized, its functionality and 
expression by tumor cells is still controversial[13]. Soluble 
VEGFR-1 was quantified in CRC cell line supernatants 
at a lower range than VEGF (mean 8.3 and 27.8 pg/mL 
respectively) and no differences were found according to 
the cellular origin (7.57 ± 2.12 and 10.67 ± 3.1, in primary 
and metastatic CRC cell lines, respectively) (Figure 4A). In 
agreement with other studies[26], a trend was observed for 
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Table 3  Association between vascular endothelial growth 
factor mRNA isoforms and vascular endothelial growth factor 
protein secretion
VEGF protein VEGF121 mRNA VEGF165 mRNA
VEGF121 mRNA  r = 0.55
P = 0.034
VEGF165 mRNA  r = 0.67  r = 0.93
P = 0.007 P = 0.000
VEGF189 mRNA  r = 0.69  r = 0.95  r = 0.92
P = 0.005 P = 0.000 P = 0.000
VEGF: Vascular endothelial growth factor.
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an inverse correlation between sVEGFR-1 and VEGF ex-
pression (data not shown), indicative of  the angiogenesis 
inhibiting role of  sVEGFR-1[13]. 
In our CRC cell lines panel, the antibody array data 
showed a lack of  expression of  sVEGFR-2 (Figure 1A). 
Given the hypothesis that earlier tumor stages are more 
dependent on the VEGF/VEGFR signaling pathway[15], 
we analyzed surface VEGFR-2 expression in CRC cells 
of  primary origin. Flow cytometry revealed a general lack 
of  surface VEGFR-2 expression in CRC cells of  medium 
to high VEGF expression, as compared to HUVEC cell 
line (Figure 4B). These findings add to the stock of  con-
troversial results to date[27,28].
DISCUSSION
Identifying the proteins responsible for the different be-
havior of  more advanced CRC tumors seems warranted 
in order to more effectively use current treatment op-
tions. Furthermore, there is a need to characterize definite 
biomarkers of  CRC metastasis to serve as prognostic 
indicators and novel interventional targets. As derived 
from our findings in vitro, the tumor microenvironment 
of  CRC metastases would be different to that of  primary 
tumors, because of  the effect of  the CRC cells secreted 
factors. Metastatic CRC cell lines are characterized by a 
greater expression of  cytokines majorly involved in me-
tastasis, migration and invasion, while being proven pro-
angiogenic effectors. MMP-1 plays an important role in 
CRC tumor invasion and metastasis[29] and MMP-9 has 
proved to be of  prognostic value in stage Ⅱ colon cancer 
patients, where tumors with higher protein expression 
had a higher recurrence rate[30]. The monocyte attractant 
chemokine I-309 has been shown to stimulate chemotaxis 
and invasion of  endothelial cells and the roles of  IL-1α 
in colon cancer angiogenesis and of  IL-2 in inflammation 
and apoptosis, seem also consistent with the metastatic 
phenotype[18,31,32]. 
Hypoxia is widely recognized as the major transcrip-
tion effector for VEGF expression[9]. However, the great-
er (two-fold increase) induction of  VEGF expression in 
hypoxia observed in primary CRC as compared to meta-
static cell lines is an interesting finding which agrees with 
recent hypotheses. Tolerance to hypoxia is frequently ac-
quired by tumor cells progressing towards more advanced 
phenotypes[15]. Our finding suggests the metastatic CRC 
molecular phenotype provides some intrinsic resistance 
to the hypoxic induction of  VEGF expression. Some 
authors have shown that hypoxia would select more ma-
lignant metastatic cells, less sensitive to anti-angiogenic 
treatment[33], to yield poorer patients outcomes[34,35]. The 
community still agrees that angiogenesis is a hallmark of  
cancer in metastatic stages[36]. However, given the broad 
angiogenic network in the tumor microenvironment, 
research should move in the direction of  investigating 
the mechanisms by which metastatic tumors depend on 
VEGF, since they seem to be different to those exploited 
by primary tumors[15]. Furthermore, with the objective of  
individualized care in mCRC, the distinct metastatic “sec-
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Figure 4  Vascular endothelial growth factor receptors expression in 
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receptor (sVEGFR)-1 expression measured by EIA is not significantly different 
between primary and metastatic colorectal cancer (CRC) cell lines; B: Flow cy-
tometry of the surface expression of vascular endothelial growth factor receptor 
(VEGFR)-2 in human umbilical vein endothelial cells (HUVEC) and the primary 
CRC cell lines HCT116, Caco2 and RKO under normoxic conditions reveals a 
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to HUVEC. NS: Not significant.
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retome” proteins emerge as alternative targets to consider 
in the management of  advanced disease.
Further to the VEGF expression profile, the pattern 
of  VEGF isoforms represents the next step to identifying 
intrinsic differences to guide treatment choice. However, 
the similar expression of  VEGF isoforms across cell 
lines does not offer clarification. Further to this finding, it 
would be of  interest to explore how VEGF transcription 
factors modulate the ratio of  VEGF isoforms as disease 
progresses, given the changes on VEGF dependence. In-
terestingly, a novel class of  VEGF isoforms, VEGFxxxb, 
generated through alternative splicing of  exon 8, has 
been recently described[37]. Studies suggest anti-angiogen-
ic or weak angiogenic properties for these isoforms[38,39]. 
Not exempt from controversy, this discovery will help in 
further defining the role of  VEGF/VEGFR signaling in 
CRC, yet still the testing techniques need refinement in 
specificity between the two classes. 
Emerging data suggest VEGF to be a growth factor 
also for tumor cells and VEGF/VEGFR signaling to reg-
ulate their expression. However, this hypothesis remains 
unproven until consolidated results on VEGF receptor 
expression on tumor cells become available[12,28]. Extensive 
work has been done on the activity of  VEGF/VEGFR-1 
signaling in CRC cells showing that it mediates cell motil-
ity and invasiveness but not cell proliferation[13]. While this 
would involve VEGF/VEGFR-1 in CRC progression and 
metastatic processes, sVEGFR-1 secretion was not found 
of  significant relevance in metastasis-derived CRC cells. 
In contrast, not so much is known about the activity of  
VEGF/VEGFR-2 in cancer cells. Reports suggest an in-
volvement in the sensitivity of  CRC cells to inhibition of  
VEGF-related survival pathways[40]. However, controver-
sial results on the VEGFR-2 expression on tumor cells to 
date[27,28], to which our results add, do not help to resolve 
this question. Definite confirmation of  the expression and 
functionality of  this pathway is necessary in order to shed 
more light on the mechanism of  action of  anti-VEGF 
therapies[40]. 
Consistent with the key role of  VEGF in the “an-
giogenic switch” and the hypoxia-resistance mechanisms 
in metastatic stages, CRC cell dependence on VEGF 
in more advanced settings seems attenuated in favor of  
other cytokines in the progression of  metastasis. Further 
investigation of  these findings and testing the signifi-
cance of  the distinct “secretome” of  CRC metastases at 
the clinic side seems warranted given the implications for 
patient outcomes. 
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Background
Identifying the proteins responsible for the different behavior of more advanced 
colorectal cancer is necessary in order to more effectively use current treatment 
options. The progressive growth of colon cancer depends on the blood vessels 
(angiogenesis) network within the tumor. Therapies targeting angiogenesis 
have emerged in the field; however, variances in the magnitude benefit lead to 
great amount of research to explain inter-individual differences. It is thought that 
different proteins or biomarkers in the tumor microenvironment are responsible 
for these facts. 
Research frontiers
The lack in understanding of biomarkers of colorectal cancer metastasis led the 
authors to set up this work. Using a novel cytokine antibody array technique, 
this work identifies the differences in angiogenesis-related protein expression 
of colorectal cancer cell lines of primary and metastatic origin. This is the first 
step prior to translation into a clinic setting, where these differences are to be 
corroborated in patients with colorectal cancer. 
Innovations and breakthroughs
The distinct profile of metastatic cell lines comprises eight proteins with different 
cellular properties, including favoring the growth of those tumor blood vessels. 
Interestingly, the classical angiogenesis marker vascular endothelial growth fac-
tor is not in such a profile, indicating that tumors in more advanced phases tend 
to rely on different mechanisms for their growth. 
Applications
The findings of this work show that a number of markers might be of value 
when determining the course of disease in colorectal cancer. Furthermore, 
these proteins arise as novel intervention targets in the metastatic colorectal 
cancer setting. 
Peer review
The researchers intent was to investigate the angiogenesis-related protein 
expression profile characterizing metastatic colorectal cancer with the aim of 
identifying prognostic markers. The subject of biomarkers of colorectal cancer 
(CRC) metastasis is not well understood up to this time. Because of that, efforts 
of authors to characterize the protein factors behind the angiogenic potential 
of CRC cell lines of metastatic origin is of great importance. This work is a next 
step forward to identify the proteins responsible for the different behavior of 
metastatic colorectal cancers and for developing new treatment options.
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